Karyopharm Therapeutics Inc. (KPTI) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

8/25

Growth 2 Margin 1 Expansion 3 Platform 2 Financial 0

latest quarter score

Earnings Reports

8
Karyopharm Therapeutics (KPTI) Q2 2026: $30.8M XPOVIO Revenue Supports Strategic Pivot to Myelofibrosis
August 13, 2026
7
KPTI Q4 2025: R&D Spend Falls 12% as Myelofibrosis Data Readout Nears
June 15, 2026
8
Karyopharm (KPTI) Q4 2025: 43% Operating Loss Improvement Sets Stage for March Myelofibrosis Data Catalyst
June 15, 2026
6
Karyopharm (KPTI) Q1 2026: Sentry OS Hazard Ratio at 0.43 Signals Potential Myelofibrosis Paradigm Shift
May 14, 2026
11
KPTI Q3 2025: Sentry Phase 3 Readout Drives $1B Myelofibrosis Ambition
November 03, 2025
9
KPTI Q2 2025: Sentry Trial Nears Completion, $1B Myelofibrosis Opportunity Takes Shape
August 11, 2025
11
Karyopharm Therapeutics (KPTI) Q1 2025: 5% Demand Growth Amid Atypical Returns Signals Resilient Commercial Execution
May 12, 2025

Browse all companies